^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    NN3201

    i
    Other names: NN3201, NN-3201, 4C9-DM1
    Company:
    Novelty Nobility
    Drug class:
    Microtubule inhibitor, c-KIT-targeted antibody-drug conjugate
    Related drugs:
    2years
    An optimized preclinical antibody-drug conjugate against cancers with cKIT overexpression or activating mutations (AACR 2022)
    This linker-payload system is the same used in ado-trastuzumab emtansine, an approved ADC for HER2-positive breast cancer. There were no significant toxicities detected at doses up to 60 mg/kg in normal mice, suggesting a therapeutic index greater than 20 times. In conclusion, NN3201 showed potent anti-tumor activity and was selected as preclinical candidate.
    Preclinical
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • KIT expression • KIT overexpression
    |
    Kadcyla (ado-trastuzumab emtansine) • NN3201